Zhao Changyun, Chen Changqin, Lu Difan, Cai Kailun, Hu Weihang, Mao Wenchao
Department of Critical Care Medicine, Zhejiang Hospital, Hangzhou, China.
Cardiovascular Ultrasound Center of the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Front Med (Lausanne). 2025 Aug 4;12:1617328. doi: 10.3389/fmed.2025.1617328. eCollection 2025.
The optimal duration of antibiotic therapy for bloodstream infections (BSI) remains a topic of ongoing debate. To address this, we conducted a meta-analysis to evaluate the efficacy and safety of 7-day and 14-day antibiotic regimens in the treatment of BSI.
We performed a comprehensive search of PubMed, Web of Science, Embase, and the Cochrane Library from the inception of these databases up to March 10th, 2025. Randomized controlled trials (RCTs) comparing 7-day and 14-day antibiotic regimens for the treatment of BSI will be included. The Cochrane risk of bias assessment tool was used to evaluate the risk of bias. The primary outcomes were all-cause mortality, 90-day mortality, while secondary outcomes included relapsed bacteremia, readmissions or prolongation of hospitalization, suppurative complications, emergence of resistance, length of stay in hospital, and adverse events. Trial sequential analysis (TSA) was then conducted.
The meta-analysis included four RCTs involving 4,794 patients. The results indicated no statistically significant differences between the 7-day and 14-day antibiotic regimens in terms of all-cause mortality (RR = 0.96, 95% CI: 0.73-1.25, = 0.75) or 90-day mortality (RR = 0.94, 95% CI: 0.80-1.10, = 0.45). When the analysis was restricted to BSI caused by Gram-negative bacteria (GNB), no statistically significant differences were observed in all-cause mortality or 90-day mortality. The 7-day antibiotic regimen was associated with a significantly shorter length of stay in hospital compared to the 14-day regimen. However, no significant differences were observed in other secondary outcomes or adverse events, including acute kidney injury (AKI), infection (CDI), diarrhea, and rash. And the TSA suggested that the current findings may have yielded a false negative conclusion.
For BSI, the 7-day antibiotic regimen was associated with a significantly shorter length of stay in hospital compared to the 14-day regimen, while demonstrated comparable efficacy and safety outcomes. From this perspective, a 7-day antibiotic regimen seems to be more advisable. However, it is imperative to conduct additional large-scale RCTs to validate and substantiate our findings.
Registration ID: CRD42024617359; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024617359.
血流感染(BSI)抗生素治疗的最佳疗程仍是一个持续争论的话题。为解决这一问题,我们进行了一项荟萃分析,以评估7天和14天抗生素治疗方案在治疗BSI中的疗效和安全性。
我们对PubMed、科学网、Embase和Cochrane图书馆从这些数据库创建至2025年3月10日进行了全面检索。将纳入比较7天和14天抗生素治疗方案治疗BSI的随机对照试验(RCT)。使用Cochrane偏倚风险评估工具评估偏倚风险。主要结局为全因死亡率、90天死亡率,次要结局包括复发性菌血症、再入院或住院时间延长、化脓性并发症、耐药性出现、住院时间和不良事件。然后进行了试验序贯分析(TSA)。
荟萃分析纳入了4项RCT,涉及4794例患者。结果表明,7天和14天抗生素治疗方案在全因死亡率(RR = 0.96,95%CI:0.73 - 1.25, = 0.75)或90天死亡率(RR = 0.94,95%CI:0.80 - 1.10, = 0.45)方面无统计学显著差异。当分析仅限于由革兰氏阴性菌(GNB)引起的BSI时,在全因死亡率或90天死亡率方面未观察到统计学显著差异。与14天治疗方案相比,7天抗生素治疗方案的住院时间显著缩短。然而,在其他次要结局或不良事件方面未观察到显著差异,包括急性肾损伤(AKI)、艰难梭菌感染(CDI)、腹泻和皮疹。TSA表明,目前的研究结果可能得出了假阴性结论。
对于BSI,与14天治疗方案相比,7天抗生素治疗方案的住院时间显著缩短,同时显示出相当的疗效和安全性结果。从这个角度来看,7天抗生素治疗方案似乎更可取。然而,必须进行更多大规模RCT以验证和证实我们的研究结果。
注册号:CRD42024617359;https://www.crd.york.ac.uk/PROSPERO/view/CRD42024617359。